This came a little quicker than I expected, but as virtually everyone at Sanofi now knows, the company's as-yet-unapproved weight loss pill, Acomplia, got a savaging from the WSJ yesterday. Three days ago I predicted that because Acomplia is also associated with depression and anxiety among some users, "I can't see the press giving Sanofi a free pass on this issue if those side effects are in any way significant."
Lo and behold, the WSJ prints a takedown piece on its front page. In addition to the side effects, the drug won't have an anti-smoking indication in the U.S., it remains delayed at the FDA, and it's had trouble getting major indications in France and Germany.
The next moment of interest will be the Sanofites' response. Will they take this lying down, preferring not to antagonize the FDA by talking loudly about their unapproved brand? Or will they rush to the barricades to defend something that hasn't made it out of the starting gate yet? Watch this space.
Acomplia is used complementary to diet and exercise to treat obese or overweight patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood. Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease. http://www.caldrugs.com/pill/Acomplia.html
Acomplia (Rimonabant, Zimulti) is a non-controlled medication used in the treatment of obesity and management of body weight. The active ingredient of Acomplia is Rimonabant. It works by blocking specific receptors in the brain and fat tissues called CB1 receptors.
http://acomplia.weightloss.lt
Posted by: Aaron | March 05, 2008 at 06:48 PM